Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 7/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | BRD2 | P25440 | 1/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.45 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456505 | 0.89 | PLK1 (0.62) | PLK1HDAC2HDAC8HDAC6CA2 | |
| SCHEMBL14025527 | 0.85 | PLK1 (0.76) | PLK1HDAC2HDAC8HDAC6CA2 | |
| SCHEMBL21104562 | 0.84 | HDAC1 (0.60) | PLK1HDAC6CA2CA1SMN1; SMN2 | |
| SCHEMBL250247 | 0.82 | HDAC6 (0.80) | PLK1HDAC2HDAC8HDAC6CA2 | |
| SCHEMBL15017778 | 0.81 | PLK1 (0.70) | PLK1HDAC2HDAC8HDAC6CA2 | |
| SCHEMBL6846675 | 0.81 | ALDH1A1 (0.63) | HDAC6CA2CA1HTT | |
| SCHEMBL1121661 | 0.81 | PLK1 (1.00) | PLK1HDAC2HDAC8HDAC6HPGD | |
| SCHEMBL10153931 | 0.81 | PLK1 (0.70) | PLK1HDAC2HDAC8HDAC6CA2 | |
| SCHEMBL9141421 | 0.81 | HDAC6 (0.64) | HDAC8HDAC6CA2CA1 | |
| SCHEMBL9450034 | 0.80 | PLK1 (0.63) | PLK1HDAC2HDAC8HDAC6CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702509-B2 | Monomer, polymer, compensation film, optical film, and display device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-07-18 | — | — | US | disclosed |
| US-11702509-B2 | Monomer, polymer, compensation film, optical film, and display device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-07-18 | — | — | US | disclosed |
| US-11608347-B2 | Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| CN-105593211-B | Indole and indazole derivatives | 豪夫迈·罗氏有限公司 | 2021-07-27 | — | — | CN | disclosed |
| US-20200377659-A1 | MONOMER, POLYMER, COMPENSATION FILM, OPTICAL FILM, AND DISPLAY DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2020-12-03 | — | — | US | disclosed |
| US-10808080-B2 | Monomer, polymer, compensation film, optical film, and display device | SAMSUNG ELECTRONICS CO, LTD. (KR) | 2020-10-20 | — | — | US | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| CN-111566105-A | Octahydropyrido [1, 2-alpha ] pyrazines as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-01 | — | — | US | disclosed |
| EP-1756051-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121080-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20040210051-A1 | N-alkanoylphenylalanine derivatives | CHEN LI (US) | 2004-10-21 | — | — | US | disclosed |
| US-6806365-B2 | ACTIVITY AS INHIBITORS OF BINDING BETWEEN VCAM-1 AND CELLS EXPRESSING VLA-4. SUCH COMPOUNDS ARE USEFUL FOR TREATING DISEASES WHOSE SYMPTOMS AND/OR DAMAGE ARE RELATED TO THE BINDING OF VCAM-1 TO CELLS EXPRESSING VLA-4. | HOFFMANN-LA ROCHER INC. | 2004-10-19 | — | — | US | disclosed |
| EP-1005446-B1 | N-AROYLPHENYLALANINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-02-25 | — | — | EP | disclosed |
| US-20030109459-A1 | N-alkanoylphenylalamine derivatives | CHEN LI (US) | 2003-06-12 | — | — | US | disclosed |
| US-6455550-B1 | INHIBITORS OF BINDING BETWEEN VASCULAR CELL ADHESION MOLECULES AND CELLS EXPRESSING VLA-4 INTEGRIN; ANTIINFLAMMATORY AGENTS | HOFFMANN-LA ROCHE INC. | 2002-09-24 | — | — | US | disclosed |
| CN-1276785-A | N-aroylphenylalanine derivs. | HOFFMANNN LA ROCHE AG F (CH) | 2000-12-13 | — | — | CN | disclosed |
| EP-1005446-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010313-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | PLK1 3803/4885HDAC2 655/4885HDAC8 555/4885 |
| US-20200377659-A1 | MONOMER, POLYMER, COMPENSATION FILM, OPTICAL FILM, AND DISPLAY DEVICE | PYM1, PADI1, COL1A1 | PLK1 3365/4885HDAC2 4834/4885HDAC8 4875/4885 |
| US-20030109459-A1 | N-alkanoylphenylalamine derivatives | VCAM1, ICAM1, SELL | PLK1 4745/4885HDAC2 1283/4885HDAC8 1859/4885 |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | PLK1 2200/4885HDAC2 463/4885HDAC8 494/4885 |
| US-11608347-B2 | Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors | PYM1, MAG, MAGI3 | PLK1 3661/4885HDAC2 3183/4885HDAC8 4549/4885 |
| US-11702509-B2 | Monomer, polymer, compensation film, optical film, and display device | PYM1, PADI1, COL1A1 | PLK1 3365/4885HDAC2 4834/4885HDAC8 4875/4885 |
| US-20040210051-A1 | N-alkanoylphenylalanine derivatives | VCAM1, ICAM1, CD59 | PLK1 4580/4885HDAC2 2608/4885HDAC8 3100/4885 |
| US-10808080-B2 | Monomer, polymer, compensation film, optical film, and display device | RAP1A, PYM1, COL1A1 | PLK1 4029/4885HDAC2 4786/4885HDAC8 4842/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | PLK1 2200/4885HDAC2 463/4885HDAC8 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.